epirubicin has been researched along with Menopause in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 9 (42.86) | 18.2507 |
| 2000's | 10 (47.62) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bella, M; Bisagni, G; Boni, C; Bruzzi, P; Camisa, R; Ceci, G; Cocconi, G; Di Blasio, B; Leonardi, F; Rondini, E; Savoldi, L | 1 |
| Amat, S; Bouchet Mishellany, F; Cayre, A; Chollet, P; De Latour, M; Feillel, V; Ferrière, JP; Le Bouedec, G; Penault-Llorca, F | 1 |
| Barats, JC; Bonneterre, J; Campone, M; Chapelle-Marcillac, I; Fargeot, P; Goudier, MJ; Guastalla, JP; Lortholary, A; Monnier, A; Namer, M; Roché, H; Schraub, S; Van Praagh, I | 1 |
| Alliot, C | 1 |
| Bell, C; Bighin, C; Boni, L; Catzeddu, T; Clavarezza, M; Del Mastro, L; Sertoli, MR; Testa, D; Venturini, M | 1 |
| Ah-See, ML; Beresford, MJ; Burcombe, R; Makris, A; Stott, D | 1 |
| Bozec, L; Campone, M; Diéras, V; Espié, M; Fumoleau, P; Kayitalire, L; Petit, T; Pouillart, P; Pujade-Lauraine, E; Serin, D; Viens, P | 1 |
| Adjadj, DJ; Aubard, Y; Benyoub, A; Bonnier, P; Clavère, P; Genet, D; Juin, P; Labourey, JL; Lebrun-Ly, V; Lejeune, C; Martin, J; Piana, L; Tubiana-Mathieu, N; Venat-Bouvet, L | 1 |
| Aaronson, NK; Buijs, C; de Vries, EG; Hupperets, P; Mourits, MJ; Nooij, MA; Post, WJ; Rodenhuis, S; Seynaeve, CM; Smit, WJ; TenVergert, EM; van der Wall, E; van Hoesel, QG; van Tinteren, H; Voest, E; Willemse, PH | 1 |
| Jones, WG; Mattsson, W | 1 |
| Bissett, D; Canney, PA; Evans, D; Habeshaw, T; Harnett, AN; Jodrell, D; Kaye, SB; Williams, M | 1 |
| Agostara, B; Cariello, S; Colucci, G; Durini, E; Gebbia, V; Giotta, F; Pacilio, G; Pezzella, G; Romito, S; Testa, A | 1 |
| Bucci, L; Caponigro, F; Di Martino, N; Facchini, G; Fei, L; Iaffaioli, RV; Mantovani, G; Santangelo, M; Tortoriello, A | 1 |
| Eaton, M; Humeniuk, V; Kent, AL; Marshall, N | 1 |
| Bertelli, G; Bruzzi, P; Del Mastro, L; Garrone, O; Guelfi, M; Pastorino, S; Rosso, R; Sertoli, MR; Venturini, M | 1 |
| Gnant, MF; Jakesz, R; Locker, GJ; Rudas, M; Schmidinger, M; Steger, GG; Taucher, S; Wenzel, C | 1 |
| Amoroso, D; Boccardo, F; Castagnetta, L; Farris, A; Genta, F; Nenci, I; Piffanelli, A; Rubagotti, A; Sismondi, P; Traina, A | 1 |
| Kawahara, T; Miyauchi, K; Mori, T; Okamura, J; Shiba, E; Takatsuka, Y; Yayoi, E | 1 |
| Boccardo, F; Bruzzi, P; Cappellini, M; Isola, G; Nenci, I; Piffanelli, A; Rubagotti, A; Santi, L; Scanni, A; Sismondi, P | 1 |
| Bartoli, C; Bonadonna, G; Brambilla, C; Coopmans de Yoldi, G; Ferrari, L; Greco, M; Luini, A; Rilke, F; Veronesi, U; Zucali, R | 1 |
| Izuo, M; Nakajima, M; Ogawa, M; Taguchi, T; Terasawa, T; Yoshida, M | 1 |
1 review(s) available for epirubicin and Menopause
| Article | Year |
|---|---|
[A comparative study of intra-arterial infusion chemotherapy and systemic chemotherapy in the treatment of locally advanced breast cancer].
Topics: Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Menopause; Middle Aged; Neoplasm Staging | 1991 |
15 trial(s) available for epirubicin and Menopause
| Article | Year |
|---|---|
Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Logistic Models; Lymphatic Metastasis; Menopause; Methotrexate; Middle Aged; Multivariate Analysis; Prospective Studies; Vincristine | 2002 |
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Immunohistochemistry; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Maximum Tolerated Dose; Menopause; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Risk Assessment; Survival Rate; Tamoxifen; Treatment Outcome | 2004 |
Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Cytarabine; Epirubicin; Estradiol; Female; Follicle Stimulating Hormone; Goserelin; Humans; Menopause; Menopause, Premature; Menstrual Cycle; Middle Aged; Ovary; Premenopause; Prospective Studies | 2006 |
Pre-treatment haemoglobin levels and the prediction of response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Databases, Factual; Disease Progression; Epirubicin; Female; Fluorouracil; Hemoglobins; Humans; Menopause; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Platelet Count; Predictive Value of Tests; Prognosis; Prospective Studies; Regression Analysis; Treatment Outcome | 2006 |
Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; France; Gemcitabine; Humans; Infusions, Intravenous; Menopause; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2006 |
Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Longitudinal Studies; Menopause; Middle Aged; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Quality of Life; Risk Factors; Tamoxifen; Thiotepa; Transplantation, Autologous | 2007 |
Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Menopause; Middle Aged; Neoplasm Staging; Neutropenia; Postmenopause; Premenopause; Recombinant Proteins | 1995 |
Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Leucovorin; Life Tables; Mastectomy, Radical; Menopause; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Remission Induction; Treatment Outcome | 1995 |
Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Epirubicin; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Indazoles; Interferon alpha-2; Interferon-alpha; Menopause; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Premenopause; Recombinant Proteins | 1995 |
Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer.
Topics: Adult; Aged; Analysis of Variance; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diethylstilbestrol; Disease Progression; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Menopause; Methotrexate; Middle Aged | 1996 |
Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Menopause; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Palliative Care; Prospective Studies; Survival Rate; Taxoids | 2002 |
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Menopause; Methotrexate; Middle Aged; Neoplasm Proteins; Receptors, Estrogen; Tamoxifen | 1992 |
[A comparative study of intra-arterial infusion chemotherapy and systemic chemotherapy in the treatment of locally advanced breast cancer].
Topics: Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Menopause; Middle Aged; Neoplasm Staging | 1991 |
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Italy; Lymph Nodes; Lymphatic Metastasis; Menopause; Methotrexate; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Prospective Studies; Random Allocation; Receptors, Estrogen; Tamoxifen | 1990 |
[A prospective randomized trial comparing epirubicin and doxorubicin in advanced or recurrent breast cancer].
Topics: Adult; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; Menopause; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Random Allocation | 1986 |
6 other study(ies) available for epirubicin and Menopause
| Article | Year |
|---|---|
Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome.
Topics: Aneuploidy; Antibiotics, Antineoplastic; Biopsy, Needle; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Humans; Ki-67 Antigen; Lymphatic Metastasis; Menopause; Middle Aged; Mitosis; Neoplasm Staging; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; S Phase; Treatment Outcome; Tumor Suppressor Protein p53 | 2003 |
Weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Immunohistochemistry; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Maximum Tolerated Dose; Menopause; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Risk Assessment; Survival Rate; Tamoxifen; Treatment Outcome | 2005 |
Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Dose Fractionation, Radiation; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Menopause; Middle Aged; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2007 |
Phase II study of weekly low-dose 4'-epi-doxorubicin in advanced postmenopausal breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Blood Cell Count; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Humans; Menopause; Middle Aged; Neoplasm Metastasis; Time Factors | 1984 |
Locally advanced breast cancer: is surgery warranted following chemotherapy?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Node Excision; Mastectomy, Simple; Menopause; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Postoperative Care; Premenopause; Radiotherapy Dosage; Retrospective Studies; Survival Rate | 1995 |
Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Mastectomy; Menopause; Methotrexate; Recurrence | 1990 |